Qorvo® Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Detects Delta and Other Circulating Variants in Two Studies
Qorvo (Nasdaq: QRVO) announced that recent studies confirm the effectiveness of the Qorvo Omnia SARS-CoV-2 Antigen Test in detecting circulating SARS-CoV-2 variants, including Delta. One study was led by Emory University and Georgia Institute of Technology for the NIH RADx initiative, while the other was conducted internally by Qorvo. The Omnia Test utilizes advanced BAW sensor technology for rapid results. Qorvo continues to validate the test’s efficacy amidst ongoing COVID-19 challenges, reinforcing its commitment to combating the pandemic.
- The Qorvo Omnia Antigen Test effectively detects all tested SARS-CoV-2 variants, including Delta.
- Studies by reputable institutions validate the test's reliability.
- Qorvo's innovative BAW sensor technology offers rapid and accurate results.
- None.
GREENSBORO, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq: QRVO), a leading provider of innovative radio frequency (RF) solutions that connect the world, announced that two recent studies confirm that the Qorvo Omnia™ SARS-CoV-2 Antigen Test efficiently detected SARS-CoV-2 variants circulating in the United States. Of the two studies, one was conducted by Emory University, Georgia Institute of Technology, and Children’s Healthcare of Atlanta for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and the other was performed by the Qorvo Biotechnologies Research and Development laboratory in Plymouth, Minnesota.
As a RADxSM-supported company, Qorvo regularly validates the Omnia SARS-CoV-2 Antigen Test for new variant response in partnership with the RADxSM variant taskforce. Qorvo also performs internal testing on recombinant antigens with mutations specific to circulating variants. Recent work has focused on the Delta variant given significant national and international interest. Both datasets support the ability to detect all variants tested, and importantly, the Delta variant.
James Klein, President of Qorvo Biotechnologies, said, “These two studies of the SARS-CoV-2 variants demonstrate the robustness of the Qorvo Omnia SARS-CoV-2 Antigen Test in detecting circulating variants in the U.S. population. Accurate test results are critical to healthcare personnel as we continue the fight against this virus. Qorvo is pleased to play an active role in curbing the spread of SARS-CoV-2 in the U.S.”
The Qorvo Omnia platform represents a novel diagnostic technique by using high frequency Bulk Acoustic Wave (BAW) sensors to achieve rapid SARS-CoV-2 (COVID-19) antigen test results. BAW sensor technology enables low limit of detection (LOD) levels similar to molecular testing capability.
For more information, visit www.qorvobiotech.com.
This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract (75N92021C00008) is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.
The Qorvo Omnia SARS-CoV-2 Antigen Test was granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) in April 2021. The test is authorized for the qualitative detection of nucleocapsid viral antigens from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of having COVID-19 by their healthcare provider within the first 6 days of symptom onset.
The Qorvo Omnia SARS-CoV-2 Antigen Test has not been FDA cleared or approved. It has been authorized by the FDA under an Emergency Use Authorization and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
About Qorvo Biotechnologies
Qorvo Biotechnologies, LLC is a wholly owned subsidiary of Qorvo, Inc. focused on the development of point-of-care (POC) diagnostics solutions leveraging Qorvo's innovative BAW sensor technology.
About Qorvo
Qorvo (Nasdaq: QRVO) makes a better world possible by providing innovative Radio Frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world.
Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries. All other trademarks are the property of their respective owners.
Media Contact: Brent Dietz Qorvo Director of Corporate Communications W + 1 336-678-7935 brent.dietz@qorvo.com |
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, and are not historical facts and typically are identified by use of terms such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements. We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under U.S. federal securities laws. Our business is subject to numerous risks and uncertainties, including those relating to fluctuations in our operating results; our substantial dependence on developing new products and achieving design wins; our dependence on several large customers for a substantial portion of our revenue; the COVID-19 pandemic materially and adversely affecting our financial condition and results of operations; a loss of revenue if defense and aerospace contracts are canceled or delayed; our dependence on third parties; risks related to sales through distributors; risks associated with the operation of our manufacturing facilities; business disruptions; poor manufacturing yields; increased inventory risks and costs due to timing of customer forecasts; our inability to effectively manage or maintain evolving relationships with platform providers; our ability to continue to innovate in a very competitive industry; underutilization of manufacturing facilities as a result of industry overcapacity; unfavorable changes in interest rates, pricing of certain precious metals, utility rates and foreign currency exchange rates; our acquisitions and other strategic investments failing to achieve financial or strategic objectives; our ability to attract, retain and motivate key employees; warranty claims, product recalls and product liability; changes in our effective tax rate; changes in the favorable tax status of certain of our subsidiaries; enactment of international or domestic tax legislation, or changes in regulatory guidance; risks associated with environmental, health and safety regulations, and climate change; risks from international sales and operations; economic regulation in China; changes in government trade policies, including imposition of tariffs and export restrictions; we may not be able to generate sufficient cash to service all of our debt; restrictions imposed by the agreements governing our debt; our reliance on our intellectual property portfolio; claims of infringement of third-party intellectual property rights; security breaches and other similar disruptions compromising our information; theft, loss or misuse of personal data by or about our employees, customers or third parties; provisions in our governing documents and Delaware law may discourage takeovers and business combinations that our stockholders might consider to be in their best interests; and volatility in the price of our common stock. These and other risks and uncertainties, which are described in more detail in Qorvo's most recent Annual Report on Form 10-K and in other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements.
FAQ
What did Qorvo announce regarding the Omnia SARS-CoV-2 Antigen Test?
Which institutions conducted the studies on Qorvo's Antigen Test?
What technology does Qorvo use in its SARS-CoV-2 Antigen Test?
Is the Qorvo Omnia Antigen Test FDA-authorized?
What is the significance of the studies conducted on the Antigen Test?
